This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nowakowski, G. S. Articles by Erlichman, C. Search for Related Content PubMed PubMed Citation Articles by Nowakowski, G. S. Articles by Erlichman, C.

A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer

Authors' Affiliations: ¹ Department of Oncology, ² Department of Molecular Pharmacology and Experimental Therapeutics, ³ Cancer Center Statistics, and ⁴ Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota

Requests for reprints: Charles Erlichman, Department of Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-3514; Fax: 507-266-5146; E-mail: erlichman.charles{at}mayo.edu.

Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of 17-allylamino-demethoxy-geldanamycin (17-AAG) administered on days 1, 4, 8, and 11 every 21 days and to examine the effect of 17-AAG on the levels of chaperone and client proteins.

Experimental Design: A phase I dose escalating trial in patients with advanced solid tumors was done. Toxicity and tumor responses were evaluated by standard criteria. Pharmacokinetics were done and level of target proteins was measured at various points during cycle one.

Results: Thirteen patients were enrolled in the study. MTD was defined as 220 mg/m². Dose-limiting toxicities were as follows: dehydration, diarrhea, hyperglycemia, and liver toxicity. At the MTD, the mean clearance of 17-AAG was 18.7 L/h/m². There was a significant decrease in integrin-linked kinase at 6 hours after infusion on day 1 but not at 25 hours in peripheral blood mononuclear cells. Treatment with 17-AAG on day 1 significantly increased pretreatment levels of heat shock protein (HSP) 70 on day 4, which is consistent with the induction of a stress response. In vitro induction of a stress response and up-regulation of HSP70 resulted in an increased resistance to HSP90-targeted therapy in A549 cells.

Conclusions: The MTD of 17-AAG on a twice-weekly schedule was 220 mg/m². Treatment at this dose level resulted in significant changes of target proteins and also resulted in a prolonged increase in HSP70. This raises the possibility that HSP70 induction as part of the stress response may contribute to resistance to 17-AAG.

This article has been cited by other articles:

				F. Cervantes-Gomez, R. Nimmanapalli, and V. Gandhi Transcription Inhibition of Heat Shock Proteins: A Strategy for Combination of 17-Allylamino-17-Demethoxygeldanamycin and Actinomycin D Cancer Res., May 1, 2009; 69(9): 3947 - 3954. [Abstract] [Full Text] [PDF]

				K. Lundgren, H. Zhang, J. Brekken, N. Huser, R. E. Powell, N. Timple, D. J. Busch, L. Neely, J. L. Sensintaffar, Y.-c. Yang, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 Mol. Cancer Ther., April 1, 2009; 8(4): 921 - 929. [Abstract] [Full Text] [PDF]

				A. K. McCollum, K. B. Lukasiewicz, C. J. TenEyck, W. L. Lingle, D. O. Toft, and C. Erlichman Cisplatin abrogates the geldanamycin-induced heat shock response Mol. Cancer Ther., October 1, 2008; 7(10): 3256 - 3264. [Abstract] [Full Text] [PDF]

				D. Song, R. Chaerkady, A. C. Tan, E. Garcia-Garcia, A. Nalli, A. Suarez-Gauthier, F. Lopez-Rios, X. F. Zhang, A. Solomon, J. Tong, et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer Mol. Cancer Ther., October 1, 2008; 7(10): 3275 - 3284. [Abstract] [Full Text] [PDF]

				A. K. McCollum, C. J. TenEyck, B. Stensgard, B. W. Morlan, K. V. Ballman, R. B. Jenkins, D. O. Toft, and C. Erlichman P-Glycoprotein-Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response Cancer Res., September 15, 2008; 68(18): 7419 - 7427. [Abstract] [Full Text] [PDF]

				E. M. Harrison, E. Sharpe, C. O. Bellamy, S. J. McNally, L. Devey, O. J. Garden, J. A. Ross, and S. J. Wigmore Heat shock protein 90-binding agents protect renal cells from oxidative stress and reduce kidney ischemia-reperfusion injury Am J Physiol Renal Physiol, August 1, 2008; 295(2): F397 - F405. [Abstract] [Full Text] [PDF]

				M. J. Ratain and R. H. Glassman Reply to the Letter to the Editor from Banerji et al Clin. Cancer Res., April 15, 2008; 14(8): 2514 - 2514. [Full Text] [PDF]

				D. Faingold, J.-C. Marshall, E. Antecka, S. Di Cesare, A. N. Odashiro, S. Bakalian, B. F. Fernandes, and M. N. Burnier Jr. Immune Expression and Inhibition of Heat Shock Protein 90 in Uveal Melanoma Clin. Cancer Res., February 1, 2008; 14(3): 847 - 855. [Abstract] [Full Text] [PDF]

				P. J. Gray Jr., M. A. Stevenson, and S. K. Calderwood Targeting Cdc37 Inhibits Multiple Signaling Pathways and Induces Growth Arrest in Prostate Cancer Cells Cancer Res., December 15, 2007; 67(24): 11942 - 11950. [Abstract] [Full Text] [PDF]

				S. Modi, A. T. Stopeck, M. S. Gordon, D. Mendelson, D. B. Solit, R. Bagatell, W. Ma, J. Wheler, N. Rosen, L. Norton, et al. Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2 Overexpressing Breast Cancer: A Phase I Dose-Escalation Study J. Clin. Oncol., December 1, 2007; 25(34): 5410 - 5417. [Abstract] [Full Text] [PDF]

				S. A. Lang, C. Moser, A. Gaumann, D. Klein, G. Glockzin, F. C. Popp, M. H. Dahlke, P. Piso, H. J. Schlitt, E. K. Geissler, et al. Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1{alpha} Autocrine Loop, and Reduces Orthotopic Tumor Growth Clin. Cancer Res., November 1, 2007; 13(21): 6459 - 6468. [Abstract] [Full Text] [PDF]

				Y. Zhang and X. Shen Heat Shock Protein 27 Protects L929 Cells from Cisplatin-Induced Apoptosis by Enhancing Akt Activation and Abating Suppression of Thioredoxin Reductase Activity Clin. Cancer Res., May 15, 2007; 13(10): 2855 - 2864. [Abstract] [Full Text] [PDF]

				R. K. Ramanathan, M. J. Egorin, J. L. Eiseman, S. Ramalingam, D. Friedland, S. S. Agarwala, S. P. Ivy, D. M. Potter, G. Chatta, E. G. Zuhowski, et al. Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers Clin. Cancer Res., March 15, 2007; 13(6): 1769 - 1774. [Abstract] [Full Text] [PDF]